
Unicycive Therapeutics, Inc. (NASDAQ:UNCY – Free Report) – Noble Financial dropped their FY2026 earnings per share (EPS) estimates for Unicycive Therapeutics in a note issued to investors on Tuesday, November 17th. Noble Financial analyst R. Leboyer now forecasts that the company will post earnings per share of ($0.80) for the year, down from their previous forecast of ($0.62). The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($1.05) per share. Noble Financial also issued estimates for Unicycive Therapeutics’ Q4 2026 earnings at ($0.33) EPS.
Several other research analysts have also recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Unicycive Therapeutics in a research report on Friday, September 4th. Guggenheim restated a “buy” rating and set a $25.00 price target (down from $37.00) on shares of Unicycive Therapeutics in a research report on Thursday, August 13th. B. Riley Financial reiterated a “buy” rating and set a $20.00 price target (down from $22.00) on shares of Unicycive Therapeutics in a research report on Wednesday, August 12th. Zacks Research upgraded shares of Unicycive Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 19th. Finally, HC Wainwright cut their target price on shares of Unicycive Therapeutics from $15.00 to $13.00 and set a “buy” rating on the stock in a research report on Tuesday, September 29th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Unicycive Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $18.25.
Unicycive Therapeutics Stock Down 5.1%
Shares of UNCY stock opened at $3.35 on Thursday. Unicycive Therapeutics has a 12 month low of $3.33 and a 12 month high of $8.74. The stock has a 50 day moving average of $4.03 and a 200-day moving average of $5.86. The firm has a market cap of $93.30 million, a PE ratio of -2.01 and a beta of 1.91.
Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) last issued its quarterly earnings data on Monday, November 16th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.10.
Institutional Investors Weigh In On Unicycive Therapeutics
Several large investors have recently made changes to their positions in UNCY. Goldman Sachs Group Inc. increased its holdings in Unicycive Therapeutics by 80.8% during the 3rd quarter. Goldman Sachs Group Inc. now owns 262,767 shares of the company’s stock worth $1,234,000 after purchasing an additional 117,463 shares in the last quarter. Dimensional Fund Advisors LP acquired a new stake in shares of Unicycive Therapeutics in the 1st quarter valued at approximately $940,000. Seven Fleet Capital Management LP grew its position in shares of Unicycive Therapeutics by 85.6% in the 2nd quarter. Seven Fleet Capital Management LP now owns 103,400 shares of the company’s stock valued at $521,000 after acquiring an additional 47,700 shares during the period. Virtu Financial LLC grew its holdings in Unicycive Therapeutics by 412.4% during the third quarter. Virtu Financial LLC now owns 59,484 shares of the company’s stock worth $279,000 after purchasing an additional 47,874 shares during the period. Finally, Bank of New York Mellon Corp acquired a new position in shares of Unicycive Therapeutics during the 2nd quarter worth approximately $248,000. Institutional investors own 40.42% of the company’s stock.
Recent Unicycive Therapeutics Headlines
These are some of the UNCY headlines that stood out recently:
- Positive Sentiment: HC Wainwright raised several 2026–27 EPS estimates, kept its Buy rating, and reiterated a $13 price target—potential support for the stock. HC Wainwright forecast article
- Negative Sentiment: A report said Unicycive’s third-quarter loss widened to $7.0 million, highlighting ongoing losses. Article on Unicycive’s Q3 loss
- Negative Sentiment: Despite raising near-term estimates, HC Wainwright cut its 2028–30 EPS forecasts substantially. Noble Financial also lowered its 2026 estimates, adding a more cautious note to the outlook. Analyst estimate reports
Unicycive Therapeutics Company Profile
Unicycive Therapeutics is a biopharmaceutical company focused on developing treatments for kidney diseases. Its lead program, oxylanthanum carbonate (OLC), is an oral phosphate binder being developed to help manage hyperphosphatemia, or elevated blood phosphate levels, in people with chronic kidney disease, including patients receiving dialysis. The company is also developing UNI-494, an investigational small-molecule therapy for acute kidney injury. These programs reflect Unicycive’s focus on conditions for which treatment options may be limited.
Featured Articles
- Five stocks we like better than Unicycive Therapeutics
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
